Implantica RefluxStop FDA Approval Sets Up J&J LINX Rivalry

The Implantica RefluxStop FDA approval is here. After a long clinical evidence build, RefluxStop has secured pre-market approval (PMA) from the US Food and Drug Administration (FDA). The nod clears US commercialisation of the device for gastro-oesophageal reflux disease (GORD).

The Implantica RefluxStop FDA approval covers an implantable, single-use device. It is used in the laparoscopic treatment of GORD. Surgeons position it on the oesophagus, just above the lower oesophageal sphincter. The device aims to correct oesophageal anatomy. This forms an anti-reflux barrier and blocks stomach acid from flowing back. The Liechtenstein-based company won a European CE mark for RefluxStop in 2018.

What backed the Implantica RefluxStop FDA approval

Implantica built its PMA case on three evidentiary modules. The first module was filed with the FDA in March 2024.

Module 1 tracked patients one year after device implantation. RefluxStop delivered an average 86% improvement in the GERD Health-Related Quality of Life (GERD-HRQL) score. The cohort was 50 enrolled patients (NCT02759094).

Only 1 of 50 patients was on regular daily PPIs at one year. That case was linked to improper device placement. 97.8% of evaluable patients reported no or only minimal occasional regurgitation episodes.

Five-year data added to the PMA package

The Implantica RefluxStop FDA approval also drew on five-year follow-up data. That readout was published in July 2025.

The paper reported median total GERD-HRQL score improvements of 90% from baseline. The evaluable cohort was 44 patients. That extends the durability signal well past the one-year window.

Forsell on the US launch plan

Implantica CEO Dr Peter Forsell said the US rollout will start with a focused approach. It will target select centres and reflux surgeons first. Training will be built in. The aim is a "solid commercial foundation for sustainable long-term growth".

Forsell continued: "We enter the US market from a position of strength, with a substantially more mature clinical and commercial foundation than is typical for a newly approved medical device."

Forsell added: "RefluxStop already has several years of commercial experience in Europe, close to 1,800 patients treated, more than 60 centres of excellence across nine European countries and published five-year clinical outcomes. Combined with our longstanding scientific engagement with many leading US surgeons and experts, we believe this provides a strong foundation to launch and scale RefluxStop in the US market."

US market context: GORD prevalence and J&J LINX

GORD is common in North America. Research indicates a prevalence of up to 28%. Symptoms include acid reflux, bloating, and severe heartburn.

RefluxStop enters a US market that already carries other GORD devices. Those devices repair or reinforce a weak lower oesophageal sphincter (LOS). The most familiar rival is Johnson and Johnson's (J&J) LINX reflux management system. LINX is a widely used implantable device. It is a flexible ring of small magnets. Surgeons place the ring around the LOS. The ring keeps the sphincter closed to prevent reflux.

Why the Implantica RefluxStop FDA approval matters

The Implantica RefluxStop FDA approval opens a second implantable option in the US anti-reflux surgery space. RefluxStop leans on anatomy correction and an anti-reflux barrier. LINX leans on a magnetic ring around the LOS. Both aim to keep patients off long-term PPIs.

For US foregut surgeons, gastroenterology teams, and hospital procurement, the Implantica RefluxStop FDA approval opens a live commercial choice. Coverage on Medigear.uk tracks the US launch, centre-of-excellence rollout, and side-by-side outcomes with LINX.

Source: Originating coverage based on Medical Device Network reporting by Ross Law, August 24, 2026, on Implantica's US FDA pre-market approval (PMA) for the RefluxStop anti-reflux device. URL: https://www.medicaldevice-network.com/